Kornimate/medical-research-clean huggingface dataset:
car-t cell induced cardiac dysfunction: a prospective study

Conditions: Lymphoma

Summary: in this observational, prospective study, patients affected by b-cell lymphoma and candidate to chimeric antigen receptor-t (car-t) cell infusion will be evaluated at three timepoints to establish the rate of cardiac dysfunction, defined according to 2022 european society of cardiology cardio-oncology guidelines. echocardiography, physical examination and cardiac/inflammatory biomarkers will be performed prior to car-t cell infusion and followed at 7 days and 1 month.

patients will perform clinical evaluation, transthoracic echocardiogram with speckle tracking analysis and blood samples (including cardiac biomarkers of damage and fibrosis) prior to cart infusion, after 7 days and 1 month following cart infusion. rate of cytokine release syndrome and use of interleukin-6 inhibitors will be also registered.

Eligibility criteria:
inclusion criteria: * age\>18 years old; * patients affected by relapsed and/or refractory diffuse large b-cell lymphoma, follicular lymphoma, primary mediastinal b-cell lymphoma, mantle cell lymphoma or b-cell lymphoblastic leukemia, candidate treatment with chimeric antigen receptor-t cell therapy at the hematology division of policlinico universitario agostino gemelli, rome; * patients with left ventricular ejection fraction \>50%. exclusion criteria: * age\<18 years old; * patients who denied to participate to the study; * patients with left ventricular ejection fraction\<50%.
effects of rhbnp in pediatrics after corrective repair of tetralogy of fallot

Conditions: Congenital Heart Defects; Tetralogy Of Fallot

Summary: the purpose of this study is to determine the effects of rhrnp on urine output and hemodynamics following corrective repair of tetralogy of fallot.

cvp(central venous pressure) and cardiac output are serious index in children with tetralogy of fallot after the corrective repair.the purpose of this study is to investigate if the therapy of rhrnp can improve the survival and life quality after the corrective repair of tetralogy of fallot.

Eligibility criteria:
inclusion criteria: * signed informed consent obtained from patient's legally acceptable representative. * pediatric patients after repair of tetralogy of fallot. exclusion criteria: * psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements. * treatment or planned treatment with another investigational drug within 3 months of screening. * known hypersensitivity to bosentan or any of the excipients * cardiogenic shock and inclination of hypotension（sbp\< 60mmhg）.

Keywords: heart defects, congenital rhbnp heart failure
an open-label extension study of stk-001 for patients with dravet syndrome

Conditions: Dravet Syndrome

Summary: stoke therapeutics is evaluating the long-term safety \& tolerability of repeated doses of stk-001 in patients with dravet syndrome who previously participated in studies of stk-001. change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.

this study is a multi-center, open-label, multiple-dose, safety extension study for patients who have completed another study of stk-001 and meet study eligibility criteria. stk-001 is an investigational new medicine for the treatment of dravet syndrome. stk-001 is an antisense oligonucleotide (aso) that is intended to increase the level of productive scn1a messenger rna (mrna) and consequently increase the expression of the sodium channel nav1.1 protein. this rna-based approach is not gene therapy, but rather rna modulation, as it does not manipulate nor insert genetic deoxyribonucleic acid (dna). stk-001 is designed to upregulate nav1.1 protein expression from the nonmutant (wild-type) copy of the scn1a gene to restore physiological nav1.1 levels. nav1.1 levels are reduced in people with dravet syndrome. stoke has generated preclinical data demonstrating proof-of-mechanism for stk-001.

Eligibility criteria:
inclusion criteria: * completed dosing with stk-001 and the end of study visit in study stk-001-ds-101 or study stk-001-ds-102, with an acceptable safety profile per investigator judgment. * had satisfactory compliance with study visits and procedures in study stk-001-ds-101 or study stk-001-ds-102 per investigator and sponsor judgment. * completed study stk-001-ds-101 or stk-001-ds-102 within 4 weeks of the start of their participation in study stk-001-ds-501 unless approved by sponsor. exclusion criteria: * met any withdrawal criteria from study stk-001-ds-101 or stk-001-ds-102. * currently treated with an antiepileptic drug (aed) acting primarily as a sodium channel blocker, as maintenance therapy, including phenytoin, carbamazepine, oxcarbazepine, lamotrigine, lacosamide, rufinamide or cenobamate. * clinically significant unstable medical conditions other than epilepsy. * clinically relevant symptoms or a clinically significant illness (in the judgment of the investigator) at screening or prior to dosing on day 1, other than epilepsy. * spinal deformity or other condition that may alter the free flow of csf or has an implanted csf drainage shunt. * treated (or is being treated) with an investigational product (other than stk-001) since participating in study stk-001-ds-101 or stk-001-ds-102. * participating in an observational study, they are excluded unless approved by the sponsor.

Keywords: pediatric epilepsy epileptic encephalopathies refractory myoclonic epilepsy severe myoclonic epilepsy in infancy
aln oatf vena cava filter

Conditions: Pulmonary Embolism

Summary: migration of a thrombus in the pulmonary circulation is the leading cause of pulmonary embolism (pe). it can be prevented mechanically by implanting a vena cava filter (vcf) in the inferior vena cava. the implation of a vcf is indicated for patients with acute pe and a contraindication to anticoagulation, with an acute deep vein thrombosis (dvt) without pe and a contraindication to anticoagulation or with acute venous thromboembolism (less than 3 months) in whom an interventional gesture at hemorrhagic and thromboembolic risk contraindicates anticoagulation. the purpose of this study is to describe the rates of implantation, removal and complications associated with the use of the optional aln oatf vcf in current practice.


Eligibility criteria:
inclusion criteria: * patient implanted with an aln oatf vcf * patient informed exclusion criteria: * minor patient * adult patient under a legal protection measure * pregnant, parturient or breastfeeding women * patient who refused to participate * patient who cannot or does not wish to be followed by the interventional radiology department

Keywords: vena cava filter
hiv eradication through cord-blood transplantation

Conditions: HIV

Summary: allogeneic hematopoietic cell transplantation from a ccr5 δ32/δ32 unrelated donor, performed for the first time in the "berlin patient", provides the only evidence to date of long-term control of hiv infection. stringent criteria to select human leukocyte antigen (hla)-matched conventional donors and low prevalence of the ccr5 δ32/δ32 homozygous genotype (\<1%) made the pursuit of "patient number 2" unsuccessful for many years. cord blood (cb) transplantation allows more permissive hla-matching criteria, making the search for hla-compatible δ32/δ32 cb units potentially feasible for transplantation of hiv-infected individuals. the investigator team involved in this trial has recently reported the first such case of ccr5 delta32/delta32 cb transplantation in a patient with hiv infection, showing a reduction of the patient's latent viral reservoir and, upon achievement of full cb chimerism, resistance of his cd4 t-lymphocytes to infection by hiv. this proof of concept led the spanish national transplant organization (ont) to generate an inventory of over 150 ccr5 δ32/δ32 cb units readily available for transplant. from this initial evidence and repository of cb units, financial support from the fundación mutua madrileña (fmm) has allowed the investigators to launch this first pilot clinical trial in this indication. the study was launched in january 2016 at hospital universitario puerta de hierro majadahonda. all hiv virology and reservoir analyses are carried out by the aids immunopathology unit at the spanish instituto de salud carlos iii. three additional transplant centres in spain will also shortly open the trial.


Eligibility criteria:
inclusion criteria: * inform consent, that will be previously approved by the board, is required in order to carry out any procedure related to the study. * hiv infection. * hematologic malignancies or any other condition with a standard indication for allogeneic hematopoietic cell transplantation. see indications by the european society for blood and marrow transplantation (ebmt). \[sureda a. et al. indications for allo- and auto-sct for haematological diseases, solid tumours and immune disorders: current practice in europe, 2015. bone marrow transplantation (2015) 50, 1037-1056.\] * lack of hla-identical related donor * availability of at least one cord blood unit ccr5 delta32 homozygous that meets quality standards. exclusion criteria: * availability of hla-identical related donor * contraindication for allogeneic stem cell transplantation.

Keywords: allogeneic hematopoietic cell transplantation
does precise delivery of remifentanil decrease coughing at emergence from anesthesia

Conditions: Cough

Summary: the investigators want to find a way to reduce or stop patients from coughing at the end of surgery when the breathing tube is taken out. the breathing tube is removed when the participants are waking up from anesthesia, and are at the point when the participants can breathe on your own. in most types of surgery, coughing at this point is common, and does not affect the participants very much, if at all. but for surgery involving the eye or the head and neck, coughing right after surgery can cause bleeding at the site of surgery. this study will use a short-acting pain drug called remifentanil at the end of surgery to prevent coughing. the investigators will give the participants this medicine for 5 to 30 minutes. the point of the study is to test if using a simple computer program to guide precise delivery of how much of the drug is given to the participants is effective at reducing or preventing coughing.


Eligibility criteria:
inclusion criteria: 1. between the ages of 18 and 80 2. asa of 1-3 3. undergoing any of the following elective cases: 1. thyroidectomy (partial or complete) 2. parathyroidectomy 3. ophthalmological surgery 4. will require endotracheal intubation. exclusion criteria: 1. lean body mass \< 20 kg, 2. bmi \> 45 3. presence of pulmonary dysfunction 4. any history of anaphylaxis to remifentanil 5. requiring the use of total intravenous anesthesia. 6. per the discretion of the anesthesia provider

Keywords: extubation
amygdala tis for depression

Conditions: Major Depressive Disorder

Summary: the current investigation employs a directed neuromodulation technique, specifically targeting the right amygdala, to ascertain its therapeutic efficacy in managing depressive episodes. the intervention's safety and efficacy will be evaluated using an assessment incorporating depressive symptomatology, cognitive abilities, and daily functions.


Eligibility criteria:
inclusion criteria: * participants must be aged between 18 and 65, with no gender restrictions; * a diagnosis of depression made by the study physician based on the diagnostic and statistical manual of mental disorders (dsm-5); * hamd-17 score of 17 or higher; * participants must not have changed their antidepressant medication regimen from 30 days prior to signing the informed consent form through the duration of the experiment; * eligible individuals or their authorized representatives must demonstrate, as assessed by the study physician, a comprehensive understanding of the study's objectives and procedures, be capable of adhering to the requirements set forth in the study protocol and provide their signature on the informed consent form. exclusion criteria: * eligible participants must not have a history of psychiatric disorders such as schizophrenia, as judged by the investigator, which may impact the evaluation of the study's efficacy; * participants must not have a history of seizures or prior episodes of epilepsy; * the presence of metallic foreign objects within the cranial structure or metallic cardiac implants; * participants must not have a diagnosis of organic brain disease nor a history of significant cranial trauma or neurosurgical intervention; * participants received electroconvulsive therapy or other physical therapies (such as transcranial magnetic stimulation therapy); * the researcher evaluated the individual's mental state and determined it to present a significant risk of suicidal ideation or behavior; * pregnant or breastfeeding; * participants who are concurrently engaged in other clinical interventional trials; * participants presenting with other circumstances that the investigator deems unsuitable for the intervention being studied.

Keywords: deep brain stimulation non-invasive ti amygdala temporal interference
use of functional magnetic resonance imaging (fmri) to study brain activation in children with irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: the purpose of the study is to map regions of brain activation following rectal stimulation in children with irritable bowel syndrome (ibs) and healthy controls.

our first aim is to compare the brain areas activated rectal stimulation in boys and girls with ibs and healthy children. our second aim is to compare the anatomic regions of the brain activated during rectal stimulation in pre and post-pubertal male and female subjects between 10-18 yrs of age.

Eligibility criteria:
inclusion criteria: * children aged 10 years to 18 years who provide written assent and whose parents provide written permission for participation * english-speaking * subjects in the ibs group will meet rome iii criteria for ibs as determined by a pediatric gastroenterologist. exclusion criteria: * other pain-related diseases, functional gastrointestinal disorders, or somatization disorder * mental retardation or pervasive developmental disorder or epilepsy * psychosis * genetic or chromosomal disorders * currently receiving psychoactive drug treatment * patients with pacemakers, metal clips used in previous surgery or other device which are not compatible with mri scanning * inability to lie still in the scanner * claustrophobia (inability to lie still in the scanner) * pregnancy * subjects who admit to substance abuse during screening * orthodontic braces

Keywords: fmri ibs brain activation
gait analysis in moderate hemophiliac patients (aqm-hemophile)

Conditions: Moderate Hemophilia; Arthropathy

Summary: the management of moderate hemophilia is less codified than those of severe patients; because these patients are theoretically less likely to bleed and therefore less likely to develop arthropathies. nowaways, the question arises as to the appropriateness of this "symptomatic" management for the prevention of the occurrence of hemophilic arthropathies. indeed, a significant number of moderate hemophiliacs seems to develop severe arthropathies that cause significant disability. however, because of the very small proportion of these patients in the total number of hemophiliacs, data are lacking on the impact of arthropathies on this population. the investigators therefore propose to include moderate hemophiliac patients in the study to carry out an evaluation of gait, using a gait analysis to determine the consequences of arthropathies, even sub-clinical ones, according to the duration of the disease's progression. in an associated way, the analysis of different clinical (joint assessment; quality of life score;...), radiological (radiographic; ultrasound (synovial thickness)), biological (level of associated factors ; other associated marker), in order to provide a complete picture of the articular situation in these patients with moderate haemophilia.


Eligibility criteria:
inclusion criteria: * have moderate hemophilia a or b. * have understood the protocol and signed its consent to participate. * patient able to perform a walking test. * patient affiliated to a social security system exclusion criteria: * pregnant women * minor * majors under guardianship or curatorship * refusal to participate; * amputee of a lower limb * need for technical walking assistance (walking sticks, walker,...). * extensive dermatitis of the lower limbs (need for sensor installation for gait analysis); * known nyha (new york heart association) grade iii or iv heart failure (resting dyspnea); * unstable angina or myocardial infarction within three months of inclusion * known severe respiratory disease; * parkinson's disease, hemiplegia or paraplegia * patient unable to understand the objectives or instructions of the study * intercurrent pathology likely to modify walking abilities
peripheral primitive fibromatosis

Conditions: Peripheral Primitive Fibromatosis

Summary: it's a monitoring study. the aim is to assess the progression free survival up to 3 years. patients are not treated until progression. search for scalability predictive factors and registration of treatments if progression.


Eligibility criteria:
inclusion criteria: * peripheral primitive fibromatosis * adults patients * peripheral primitive fibromatosis proved by biopsy * peripheral primitive fibromatosis r2 resected for which monitoring is decided * mri realized before inclusion * patient information and informed consent signed exclusion criteria: * local recur * head and neck topography * primitive fibromatosis r0 or r1 resected * specific medical treatment of fibromatosis * patient already included in an other clinical trial with an experimental molecule * persons deprived of liberty * impossibility to submit to the trial's medical follow-up for psychological, geographical or socials reasons * previous history of cancer * counter indication to the realization of an mri

Keywords: proved by biopsy
management of patients with high c-reactive protein after scheduled resection of colorectal cancer

Conditions: Colon and/or Rectal Resection With Anastomosis for Cancer

Summary: anastomotic fistula is the most feared complication after surgical resection of colorectal cancer (ccr). it occurs in 6 to 15% of patients. beyond the risk of death in the immediate postoperative period, the pain that it induces, the resources required for its management, the need for stomata with a negative impact on patients' quality of life and the prolongation of hospitalization, it also has a now-recognized adverse effect on long-term survival. the early detection of this complication may limit its impact. c-reactive protein (crp) has proved to be an early, reliable marker of the onset of infectious complications of colorectal surgery. however, the diagnostic procedure to implement in these patients is not at all codified, since this population concerned by systematic crp assay in the postoperative period is very recent. the procedures to implement in these patients so that they can obtain the maximal benefit of an early diagnosis have not yet been established. an algorithm for the proactive clinical management must be drawn up to be able to confirm or rule out the presence of a fistula as soon as a high level of crp is detected, and to propose a quick treatment to ensure that patients benefit from this early diagnosis.


Eligibility criteria:
inclusion criteria: * patients aged 18 and older, * with a crp level \> 140 mg/l at d3 or crp \> 125 mg/l at d4 following colon and/or rectal resection with anastomosis (protected or not by an upstream stoma) * without clinical signs of severe peritonitis (fever, severe sepsis, generalized abdominal contracture) * who have provided written informed consent. exclusion criteria: * patients who have undergone intraperitoneal chemotherapy in the context of the surgical treatment for peritoneal carcinomatosis * patients with a diagnosis of another infection that could explain the high crp level, * patients who underwent eventration repair at the time of the colorectal resection * patients with an obvious indication for revisit surgery * persons without health insurance cover * adults under guardianship * pregnant or beast-feeding women
radiation therapy in uterine cancer: dosimetry analysis, clinical implication, and survival analysis

Conditions: Endometrial Cancer

Summary: we wish to study radiation therapy in uterine cancer, focusing on dosimetry analysis, clinical implication, and survival analysis.

we wish to study radiation therapy in uterine cancer, focusing on dosimetry analysis, clinical implication, and survival analysis.

Eligibility criteria:
inclusion criteria: * women with uterine cancer (stage i - iv) treated in national taiwan university hospital, from january 2010 to september 2019. exclusion criteria: * women with uterine cancer (stage i - iv) not treated in national taiwan university hospital, from january 2010 to september 2019.
impact of sleep restriction on performance in adults

Conditions: Sleep; Obesity; Sleep Restriction

Summary: the overall goal of this project is to look at the effects of long-term, sustained sleep restriction (sr) in adults, and assess the effects on mood and cognitive and physical performance.

chronic sleep restriction (sr) is highly prevalent in today's modern society. artificial light, portable electronic devices, and 24-h services have allowed individuals to remain active throughout the night, leading to reductions in sleep duration. ssd has been linked to obesity and our laboratory has been interested in establishing whether sleep could be a causal factor in the etiology of obesity. given the increasing prevalence of obesity over the past 5 decades, coinciding with the marked reduction in sleep duration, further exploration into the role of sleep as a risk factor for obesity could provide additional ammunition in the fight to prevent further increases in the incidence of obesity. this study will be a randomized, crossover, outpatient sr study with 2 phases of 6 weeks each, with a 6 week wash-out period between the phases. sleep duration in each phase will be the participant's regular bed- and wake times during the habitual sleep (hs) phase and hs minus 1.5 hours in the sr phase. during the hs phase, participants will be asked to follow a fixed bedtime routine based on their screening sleep schedule. during the sr phase, participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time.

Eligibility criteria:
inclusion criteria: * bmi 25-29.9 kg/m2 * have at least one obese parent * habitually sleep 7-9 hours a night * free of any current and past sleep and psychiatric disorders, including eating disorders, diabetes or cardiovascular disease (cvd) (i.e., normal scores on: pittsburgh quality of sleep questionnaire epworth sleepiness scale, berlin questionnaire, sleep disorders inventory questionnaire, beck depression inventory, composite scale of morningness/eveningness, three factor eating questionnaire) * all racial/ethnic groups exclusion criteria: * smokers (any cigarettes or ex-smoker \< 3 years) * neurological, medical or psychiatric disorder * diabetics * eating and/or sleep disorders * contraindications for mri scanning * travel across time zones within 4 weeks * history of drug and alcohol abuse * shift worker (or rotating shift worker) * caffeine intake \> 300 mg/d * heavy equipment operators * commercial long-distance drivers

Keywords: body weight habitual sleep